Abstract:Abstract INTRODUCTION: Lung cancer is the leading cause of cancer-related deaths worldwide. KRAS is the most frequent mutated driver gen in lung adenocarcinoma (LUAD). KRASG12C inhibitors (G12Ci) have revealed promising results in the clinic, having being approved two G12Ci for the treatment of LUAD patients, which marks the first approved targeted therapy for KRAS-mutant tumors. Nevertheless, these therapies face the same limitation as other targeted therapies, the therapeutic potential of these inhibitors can be impaired by resistance mechanisms. Deciphering resistance mechanisms to G12Ci is of prime relevance to predict which patients may benefit from these therapies and to propose resistance-overcoming therapeutic strategies for maximizing therapeutic impact of these inhibitors. MATERIAL AND METHODS: We generated 10 acquired resistant LUAD cell lines to G12Ci (Sotorasib and Adagrasib), exposing sensitive cells to increasing concentrations of drugs. All the acquired resistant models were characterized at the proteomic (phospho-Array and Western Blot) and transcriptomic (WTS) levels to find signatures that define the resistance.The efficacy of G12Ci was tested in vitro in a panel of 8 cell lines and 7 PDX-derived organoids (PDXDO) models and in vivo in 7 patient-derived xenografts (PDX) models to classify them as resistant, sensitive or partially sensitive. The efficacy of the combination of FGFR1 and G12Ci was tested in vitro in the panel of 10 acquired resistant cell lines but also in the parental cell lines and PDXDOs (sensitive and intrinsic resistant) and in vivo in the intrinsic resistant PDXs. RESULTS AND DISCUSSION: The characterization of 10 acquired resistant cell lines at the proteomic and transcriptomic levels showed differences in the expression and/or activation of Fibroblast Growth Factor Receptors (FGFRs) in more than 50% of them. The combination of KRASG12C and FGFR1 inhibitors in all acquired resistant cell lines showed efficacy, regardless of whether acquired resistance was mediated or not by FGFR1 overexpression/overactivation.In addition, the combination of KRASG12C and FGFR1 inhibitors showed more efficacy than the monotherapies in most intrinsically resistant cell lines, PDXDOs and PDXs models. Finally, we tested the combination with FGFR1i in sensitive or partially responsive models, observing an improvement in efficacy compared to monotherapy with G12Ci. CONCLUSIONS: The activation or overexpression of FGFR1 acts as a mechanism of acquired resistance to KRASG12C inhibitors.-The combination of FGFR and KRASG12C inhibitors is effective as an acquired/intrinsic resistance-overcoming therapeutic strategy in cell lines, PDXDOs and PDXs models.-The combination of FGFR and KRASG12C inhibitors is also synergistic for sensitive models, which could maximize therapeutic impact of KRASG12C inhibitors. Citation Format: Alba Santos, Patricia Plaza, Marta Jimenez, David Gómez-Sánchez, Luis Paz-Ares, Irene Ferrer. Combination of KRASG12C and FGFR1 inhibitors as a resistance-overcoming therapeutic strategy for maximizing therapeutic impact of KRASG12C inhibitors [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1930.

Multiple Initiatives to Conquer KRAS G12C Inhibitor Resistance from the Perspective of Clinical Therapy

Resistance Looms for KRAS G12C Inhibitors and Rational Tackling Strategies.

KRAS G12C inhibitor combination therapies: current evidence and challenge

Covalent inhibitor targets KRasG12C: A new paradigm for drugging the undruggable and challenges ahead

Targeting KRAS G12C Mutations in Colorectal Cancer.

More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C

The KRAS-G12C inhibitor: activity and resistance

Targeting KRAS Mutant Cancers: from Druggable Therapy to Drug Resistance

Abstract A072: Strategies to improve KRAS G12D inhibitor (MRTX1133) therapy in pancreatic ductal adenocarcinoma

Targeting KRASG12C-Mutated Advanced Colorectal Cancer: Research and Clinical Developments

Combining EGFR and KRAS G12C Inhibitors for KRAS G12C Mutated Advanced Colorectal Cancer

Abstract 401: Developing KRAS G12C Inhibitor-Resistant Tumor Models for Efficacy Evaluation of Next-Generation Anticancer Therapies

Research Progress on Small Molecule Inhibitors Targeting KRAS G12C with Acrylamide Structure and the Strategies for Solving KRAS Inhibitor Resistance

Recent advances in the development of inhibitors targeting KRAS-G12C and its related pathways

Advances in KRAS mutation inhibition in metastatic colorectal cancer

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges

Structural perspectives on recent breakthrough efforts toward direct drugging of RAS and acquired resistance

Abstract 1930: Combination of KRASG12C and FGFR1 inhibitors as a resistance-overcoming therapeutic strategy for maximizing therapeutic impact of KRASG12C inhibitors

Targeting KRAS in pancreatic cancer: Emerging therapeutic strategies

Abstract IA-05: Targeting KRAS for pancreatic cancer treatment

RAS-ON inhibition overcomes clinical resistance to KRAS G12C-OFF covalent blockade